Wow. Brean Murray analyst just issued report. Says SFP WILL NOT be approved!
Pretty scathing report. Very critical of the PhIII trial.
Go to Adam Feurerstein's Twitter page. He has posted links to Brean analyst comments at about 11am.
FYI, Adam notes that Brean analyst is a big KERX bull. Is that skewing his analysis?
I hear what analyst is saying. The PhIII trial is somewhat uncoventional in design, duration, and endpoints, but it had to be. If they convene an FDA Advisory Panel, much will depend on who is on it. Then of course the 'new' FDA can do what they want after the fact. And right now the new FDA is much more likely to approve something that cuts medical costs. Maybe they'll do approval with post approval durability study requirement.
The easy money was made from $3.10 when they did the stock offering. THAT was a no brainer. Lots more uncertainty now. I've been out of the stock for a couple weeks now, I'm always early getting out.